Status:
WITHDRAWN
Development of a Scalable Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
Sheppard Pratt Health System
Truth Initiative
Conditions:
Tobacco Cessation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
All patients with serious mental illness are abstinent while in the hospital for a psychiatric admission yet almost all return to smoking after discharge. The investigators propose to adapt a digital ...
Detailed Description
Persons with serious mental illness (SMI, schizophrenia, bipolar disorder, recurrent depression) are a socioeconomically disadvantaged group and die on average 10-15 years earlier than those in the ge...
Eligibility Criteria
Inclusion
- Age 18 or greater
- Diagnosis of serious mental illness (schizophrenia, schizoaffective disorder, bipolar disorder, or major depression)
- Current smoker \[prior to admission, smoked at least one cigarette or small cigar per day in the past month (unless restricted, e.g. due to ER/hospital visit) and smoked at least 100 cigarettes lifetime\]
- Interested in remaining quit after hospital discharge or quitting within the following 30 days
- Expected Internet use at least several times a week post-discharge and ownership of mobile device with text messaging plan post-discharge
- Sufficiently stable and cooperative to engage in the intervention, operationalized as not on a nursing observation level that indicates high acuity/safety concerns and has participated in a majority of hospital unit activities as documented in the chart during the hospital stay so far
Exclusion
- Intellectual disability (DSM5 317, 318), traumatic brain injury, or deafness.
- Homeless prior to admission or anticipated to be homeless at discharge.
- Discharge to a residential setting where smoking is prohibited.
- Medical condition for which the use of nicotine replacement therapy (NRT) is contraindicated including pregnant, planning to become pregnant, or breastfeeding; within 4 weeks post myocardial infarction; severe arrhythmia, severe angina pectoris; peptic ulcer; severe renal failure; poorly controlled insulin-dependent diabetes; severely uncontrolled hypertension; peripheral vascular disease.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04340102
Start Date
July 1 2020
End Date
June 1 2022
Last Update
November 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201